Skip to main content
Daniel Weisdorf, MD, Oncology, Minneapolis, MN

Daniel J Weisdorf MD


Professor, Medicine, University of Minnesota Medical School

Join to View Full Profile
  • 516 Delaware Street SeMMC 480, PWB 14-110Minneapolis, MN 55455

  • Phone+1 612-624-3101

  • Fax+1 612-625-6919

Dr. Weisdorf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Minnesota
    University of MinnesotaFellowship, Hematology and Medical Oncology, 1978 - 1981
  • Michael Reese Hospital and Medical Center
    Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1975 - 1978
  • Chicago Medical School at Rosalind Franklin University of Medicine and Science
    Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1975

Certifications & Licensure

  • ND State Medical License
    ND State Medical License 2022 - 2027
  • MN State Medical License
    MN State Medical License 1978 - 2026
  • IL State Medical License
    IL State Medical License 1976 - 1987
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Amphiregulin in Intestinal Acute Graft-Versus-Host Disease: A Possible Diagnostic and Prognostic Aid  
    Brittney Schultz, Bruce R Blazar, Daniel J Weisdorf, Shernan G Holtan, Alexander Khoruts, Armin Rashidi, Margaret L MacMillan, Khalid Amin, Byron P Vaughn, Nature
  • Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors  
    Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
  • Narrowing the Gap for Hematopoietic Stem Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and Trends  
    Marcelo Pasquini, Daniel Weisdorf, Nature

Abstracts/Posters

  • Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...
    Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) _ a Report from the BMT Survivor St...
    Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Stroke Risk in Blood or Marrow Transplant (BMT) Survivors _ a Report from the BMT Survivor Study (BMTSS)
    Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Burden of Morbidity Borne By Survivors of Multiple Myeloma (MM) Treated with Autologous Blood or Marrow Transplant (BMT) - Results of the BMT Survivor Study (BMTSS) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Grant Support

  • Enhancing The Safety Of Allogeneic TransplantationNational Heart, Lung, And Blood Institute2011
  • Clinical Transplantation Exploiting NK Cell ActivityNational Cancer Institute2005–2011
  • Enhanced GVHD Prophylaxis In Allogeneic Stem Cell TransplantationNational Heart, Lung, And Blood Institute2006–2010
  • Mt2003-23:Non-Myeloblative Haploidentical HSCT With NK Cell Infusions In High RINational Center For Research Resources2007
  • Non-Myeloblative Haploidentical HSCT With NK Cell Infusions In High Risk MyeloidNational Center For Research Resources2006

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: